Investigation of the beta 2 adrenergic receptor (B2-AR) pathway in canine hemangiosarcoma by Portela, Roberta
 
 
 
 
 
INVESTIGATION OF THE BETA 2 ADRENERGIC RECEPTOR (Β2-AR) PATHWAY IN 
CANINE HEMANGIOSARCOMA 
 
 
 
 
 
 
BY 
 
ROBERTA PORTELA 
 
 
 
 
 
 
 
 
THESIS 
 
Submitted in partial fulfillment of the requirements  
for the degree of Master of Science in VMS – Veterinary Clinical Medicine  
in the Graduate College of the  
University of Illinois at Urbana – Champaign, 2014 
 
 
 
 
Urbana, Illinois 
 
 
Master’s Committee:  
 
 Assistant Professor Jackie M. Wypij, Chair 
Associate Professor Timothy M. Fan 
Assistant Professor Stephane Lezmi 
  
 
	   ii	  
ABSTRACT 
Canine hemangiosarcoma is a highly metastatic cancer arising from vascular endothelial cells. It 
is one of the most aggressive canine cancers and most dogs die from this disease within a few 
months of the diagnosis. Despite advancements in veterinary oncology, there has been minimal 
improvement in the overall survival time even with standard treatment, which includes surgery 
and chemotherapy. Propranolol, an oral drug originally developed for the treatment of 
cardiovascular diseases, has been successfully used for the treatment of infantile hemangioma 
which is a benign neoplasia of vascular endothelial cells. Propranolol blocks adrenergic 
receptors, which would otherwise bind to catecholamines responsible for the “stress signal” 
leading to many physiologic changes. Stress has been implicated in many models of 
carcinogenesis and tumor progression. Given the relationship between stress and cancer, as well 
as similarities between canine hemangiosarcoma and infantile hemangioma, we sought to 
investigate the presence of the beta 2 adrenergic receptor and the effects of propranolol in canine 
hemangiosarcoma. We demonstrated the presence of the beta 2 adrenergic receptor via 
immunohistochemistry in all 18 tissue samples of spontaneous canine splenic hemangiosarcoma 
and in canine hemangiosarcoma cell lines Fitz and DEN, cell line receptor expression was also 
confirmed with Western blot. Src, a possible intermediary downstream protein involved in 
adrenergic signaling was also investigated and both Fitz and DEN exhibited the presence of the 
Src protein in Western blot. Activation of this pathway would involve phosphorylation of Src 
upon catecholamine binding to the receptor, which was investigated through Western blot. Fitz 
and DEN exhibited basal phosphorylation of Src and after treatment with norepinephrine, and 
Fitz exhibited greater phosphorylation (23% increase compared to basal control) after 60-minute 
exposure to the agonist. Fitz cells were pretreated with a biologically achievable dose of 
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propranolol followed by the agonist, and a modest decrease in phosphorylation was observed 
(11% decrease compared to basal level). Further investigation into the biological effects of 
propranolol in Fitz and DEN revealed a decrease in VEGF secretion, increase in proliferation 
and decrease in cell migration. Reduction in VEGF secretion was evaluated via ELISA and it 
was present at propranolol doses greater than 10 µM for DEN and Fitz, achieving a maximum 
reduction of 21% in DEN and 44% in Fitz compared to untreated cells. Cell proliferation was 
measured through MTS assay, which revealed an increase in cell proliferation only in Fitz cells 
treated with 0.1 µM of NE (25% increase) and cells treated with 0.1 µM of propranolol (30% 
increase). Cell migration was evaluated with a scratch assay and was decreased only when cells 
were treated with propranolol at a high dose (100 µM). Taken together, the findings of this study 
show that beta 2 adrenergic receptors are expressed by canine hemangiosarcoma, Src may be 
involved in the downstream signaling from the receptor and blockade of the receptor leads to 
mild to moderate effects in cell angiogenesis, proliferation and migration.  
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CHAPTER 1 
INTRODUCTION 
 Canine hemangiosarcoma (cHSA) is a malignant neoplasm of endothelial cells that 
affects many species, being more frequent in dogs [1-3]. This disease is highly metastatic and the 
prognosis is poor, with a median survival time of about 6 months with standard therapy, which 
involves surgery and chemotherapy treatment [4]. Limited advancements have been made to 
improve survival time therefore novel therapies are needed. Drug repositioning, which uses 
known drugs for alternative purposes (treatment of new diseases), is a strategy that can be 
pursued with the advantage of being of lower cost (pharmacokinetics and pharmacodynamics are 
already known; drugs already in the market can be selected for their cost) and known tolerability. 
Recently, propranolol has received attention for its effects on the treatment of infantile 
hemangioma (IH), a benign neoplasm of endothelial cells. It was accidentally discovered while 
treating infants with hypertension that propranolol (a β-adrenergic receptor antagonist) has 
activity against IH, even in treatment-resistant cases [5]. This prompted many studies, mostly 
clinical [6-11], looking at the effects of propranolol as an anti-neoplastic drug. Since both cHSA 
and IH are tumors of endothelial cell origin, we developed an interest in investigating the effects 
of propranolol in cHSA. Parallel to IH and the recent propranolol discovery, there is also a link 
between stress and cancer. Stress is physiologically described as the binding of catecholamines 
to the adrenergic receptors, which mediate the “fight-or-flight” response necessary for survival 
of an organism. An interesting hypothesis is that this adrenergic signaling may also be 
functioning to maintain survival and/or progression of neoplastic cells exposed to the same 
catecholamines released during stressful situations, which are common during diagnosis and 
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treatment of cancer.  To further support this hypothesis, studies linking breast cancer survival 
and β-blockers have been published suggesting that inhibition of the β-adrenergic signaling 
pathway can reduce breast cancer progression, recurrence, metastasis and mortality [12, 13]. 
Many other studies supporting the role of the β-adrenergic pathway in cancer development have 
been described and will be discussed in the next section.  
 We hypothesized that cHSA expresses the receptors necessary for adrenergic signaling 
(β2-AR), an intermediary kinase (Src) is involved in the signaling pathway downstream from the 
receptor and propranolol treatment would lead to decrease in cell proliferation, angiogenesis and 
migration.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1. Stress and tumorigenesis 
 The process of tumorigenesis and metastasis has been extensively studied in the scientific 
community. Many environmental components have been implicated in cancer development and 
new compounds with carcinogenic activity are frequently being discovered. Stress is one 
environmental component that may influence the carcinogenic process and potentiate 
tumorigenesis. Stress is defined as “A state of mental or emotional strain or tension resulting 
from adverse or very demanding circumstances” and “Pressure or tension exerted on a material 
object” [14, 15]. In modern life, people are subjected to stress from many different aspects. 
Stressful experiences include physical stressors such as pathogens and toxins, and psychological 
stressors such as major life events, trauma, abuse, or factors related to the environment in the 
home, workplace or family [16].  
In 1936, Hans Selye defined stress physiologically as the state in which the 
sympathoadrenomedullary system and the limbic-hypothalamic-pituitary-adrenal axis are co- 
activated [16, 17]. From a biological standpoint, it is known that stress, whether physical or 
mental, culminates in the release of hormones named catecholamines, which mediate the “fight-
or-flight” responses causing activation of the sympathetic nervous system [19]. The most 
abundant catecholamines are epinephrine (E), norepinephrine (NE) and dopamine, which are 
released from the chromaffin cells of the adrenal medulla and from neuro-muscular junctions 
[19, 20]. In humans, acute stress can elevate the levels of norepinephrine and epinephrine by 
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greater than 10-fold in only a few seconds, although chronic stress can lead to fluctuations on the 
catecholamine levels as well [19, 20].  
Cancer patients are subjected to stress from different aspects, from dealing with the 
acceptance of a terminal disease (sometimes associated with anxiety and depression) to the 
homeostatic effects of stress on inflammation, immunocompetence, and cancer initiation or 
progression [19, 21-28]. 
Evaluating stress in canine patients is difficult, especially the psychosomatic aspects. 
Physiologically there have been attempts at quantifying mediators of stress signaling. Increase in 
plasma epinephrine and norepinephrine levels in dogs was documented in a study that compared 
levels of these catecholamines in groups subjected to environmental stress of blood collection 
immediately after arrival to the laboratory versus 15 minutes after arrival, indicating the rapid 
fluctuation of these hormones under different stress conditions [29]. Levels of catecholamines in 
dogs subjected to various stressful stimuli were measured and in the literature they ranged 
around 65 to 239 pg/mL for epinephrine, 145 to 524 pg/mL for norepinephrine and 20-437 
pg/mL for dopamine [14, 29]. The release and degradation of catecholamines is variable and thus 
the concentration of these hormones can differ significantly across different tissues and within 
the circulating blood [2]. In humans, the difference can be in the order of nanomolar for 
circulating NE versus micromolar concentrations in the tissue microenviroment [30]. 
2.2. Adrenergic pathway 
 Catecholamines mediate adrenergic signaling via receptors in target cells. Receptors 
include α1A,B,D; α2A,B,C; β1,β2 and β3 and are present in a wide variety of cells and tissues, 
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including central nervous system (CNS), lungs, liver, pancreas, kidney, adrenal glands, breast, 
ovary, prostate, vasculature, bone marrow and cells of the immune system (macrophages, mast 
cells, lymphocytes) [19, 20]. The expression of β1 and β2 adrenergic receptors (AR) has been 
extensively studied in the cardiovascular system, with high expression occurring in cardiac 
myocytes and vascular smooth muscle cells [31]. These receptors belong to a family called G-
protein coupled receptors (GPCRs) [32], which contain seven transmembrane “serpentine” 
segments with the N-terminal facing the extracellular space and the C-terminal immersed in the 
cytoplasm. When the ligand binds to the extracellular domain of the receptor, the receptor 
undergoes a conformational change, which will then activate the G-protein located in the 
intracellular space. The G-protein is composed of a α, β and γ units, with the α and γ subunits 
having lipid tails that covalently attach the protein to the cell membrane. In the absence of ligand 
binding, the resting G-protein’s alpha subunit is bound to GDP (guanosine diphosphate). When 
the signal is initiated by catecholamine binding, the receptor undergoes a conformational change 
and GDP is replaced by GTP (guanosine triphosphate) in the alpha subunit of the G-protein. This 
protein detaches from the transmembrane receptor and moves on to activate other downstream 
proteins (Fig. 2.1). Inactivation of the protein occurs when phosphatase activity removes a 
phosphate group from GTP transforming it back to GDP form [33]. 
Beta 2 adrenergic receptors (β2-AR) are the focus of this project due to its demonstrated 
expression in different human vascular tumors [34]. These receptors activate adenylyl cyclase 
which in turn will catalyze the conversion of ATP to cyclic AMP (cAMP). Cyclic AMP can act 
as a secondary messenger itself or it can bind to other downstream proteins, such as protein 
kinase A [33, 35, 36]. Protein kinase A can phosphorylate other target proteins including cAMP-
responsive element binding protein/activating transcription factor (CREB/ATF) and β-adrenergic 
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receptor kinase (BARK) [19]. Upon continuous stimulation, the receptor eventually becomes 
inactivated by the inability to bind to G-proteins. That is achieved by phosphorylation of the 
intracellular portion of the receptor by BARK, and the phosphorylated protein binds to β-
arrestin, which blocks the connection between the receptor and the G-proteins (Fig. 2.2). β-
arrestin also can function as an adaptor protein, and is this way that it recruits Src to become 
bound to the β2-AR [37]. Furthermore, it has also been shown that cAMP/PKA mediates NE-
induced activation of Src [38]. 
 Src is a non-receptor tyrosine kinase ubiquitously expressed in many tissues, and plays 
an important role in transmitting signals from the cell surface to the nucleus via phosphorylation 
of tyrosine residues of intracellular proteins [39]. Src is involved in the maintenance of normal 
cell homeostasis including cell proliferation, survival, maintenance of cytoskeleton, cell adhesion 
and motility [38, 39]. Src is overexpressed in many human malignancies, including colorectal, 
breast, prostate, pancreas, head and neck carcinoma, lung carcinoma, glioma, melanoma and 
sarcomas [38, 40, 41]. A recent study has demonstrated relationship between increased 
phosphorylation of Src caused by NE stimulation and tumor growth and progression in ovarian 
carcinoma murine models, assessed as number of nodules and tumor weight. Propranolol, a non-
selective β-blocker (described in detail later in this chapter) successfully counteracted the effects 
of stress and of adrenergic agonists (isoproterenol and terbutaline) evidenced by decreased tumor 
weight and number of nodules in mice, which was similar to control (non-stressed or non-treated 
mice) [38]. Src has been also implicated in NE-stimulated vascular endothelial growth factor 
(VEGF) production by adipocytes [42, 43]. VEGF is a cytokine known to stimulate angiogenesis 
in both normal and neoplastic tissue. In addition, it was demonstrated that Src is present in 
canine HSA cell lines and its reduced expression was linked to a decrease in cell viability [44]. 
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2.3. Adrenergic pathway and molecular pathogenesis of cancer  
2.3.1 Breast cancer 
 The β2-AR and its signaling pathways have been extensively studied in human oncology. 
In breast cancer, preclinical models suggest that this pathway may influence breast cancer 
progression through: 1) increased tumor cell survival after exposure to chemotherapeutic agents; 
2) increased breast cancer cell proliferation; 3) altering the tumor microenvironment in 
angiogenesis and inflammatory response [27].  
 At therapeutic levels, β-blockers do not seem to be directly cytotoxic; rather the β-AR 
blockade may inhibit catecholamine signaling that normally would lead to pro-tumorigenic 
effects (cell survival, proliferation, migration, angiogenesis) [45]. Therefore, research efforts are 
now focused on the ability of β-blockers to inhibit cancer progression in already established 
cancers. In one study using an orthotopic mouse model looking at the effect of chronic stress in 
breast cancer progression, mice were injected with luciferase-transfected breast cancer cells into 
the 4th mammary pad and physically restrained for 2 hours daily for 20 days, while the control 
group was not subjected to stress. The results showed a 37-fold increase in metastasis to the 
lungs and 67% increased metastasis to the lymph nodes in the stressed group compared to 
control [30]. In a separate experiment, mice were pre-treated with propranolol prior to tumor 
inoculation and stress stimuli. There was an increased expression of β2-AR in tumors in 
propranolol-treated animals and propranolol significantly decreased the metastatic burden in 
stressed animals. There was no change in metastasis for non-stressed animals, and treatment did 
not affect primary tumor growth in either group [30]. This study provided some objective 
evidence of the role of adrenergic signaling and breast cancer progression. 
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Catecholamines alter the cytokine profile of the bone microenvironment and promote the 
incidence of metastatic colonization by breast cancer cells. Receptor activator of nuclear factor 
kappa-B ligand (RANKL) is a protein involved in bone remodeling as well as dendritic cell 
maturation and is secreted by osteoblasts in response to sympathetic activation. RANKL 
stimulates breast cancer migration and bone colonization and is recognized as a crucial factor for 
cancer cell motility in addition to its well-established role in tumor-induced osteolysis [46]. This 
pathway was inhibited by propranolol therapy [47]. Activation of the sympathetic system 
promoted bone metastasis in a mouse model of breast cancer. Stimulation of the β2-AR induced 
RANKL expression in bone marrow osteoblasts and increased migration of metastatic MDA-
MB-231 mammary carcinoma cells in vitro. Mice models of bone metastasis subjected to chronic 
stress had sympathetic activation blocked by propranolol. Sympathetic nerves inhibit osteoblast 
proliferation and regulate hematopoietic stem cell proliferation, survival and trafficking [48, 49]. 
Norepinephrine released from the sympathetic nerves stimulate the formation of osteoclasts [50].  
 Perhaps one of the most commented serendipitous discovery was that women who 
took β-blockers (specifically propranolol) for cardiovascular disease were found to be 
significantly less likely to die of their cancer, and less likely to present at higher stages of the 
disease, compared to women who did not take propranolol [12]. Another study showed a 57% 
reduced risk of metastasis and a 71% reduction in breast cancer mortality after 10 years [13]. 
Further evidence also showed that β-blocker intake was associated with improved relapse-free 
survival but not overall survival in patients with breast cancer, including triple-negative tumors 
which are tumors negative for epidermal growth factor receptor (HER2), progesterone receptor 
(PR) and estrogen receptor (ER) [51]. Relapse is more frequent among triple-negative breast 
cancer patients, especially within the first 3 years of diagnosis, compared to patients with ER 
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positive tumors [52, 53]. High β2-AR expression was found in tumors containing estrogen 
receptors that were hormonally positive, and patients carrying these tumors had a worse 
prognosis five years later, coincidentally with the discontinuation of tamoxifen therapy. The 
prognosis was good within the first five years, hinting at a possible advantage of combination 
therapy with propranolol, which could have an impact in breast cancer survival [54]. 
Despite some encouraging published evidence on the benefits of propranolol in cancer 
patients, there is still some controversy. There are studies suggesting an increased risk or no 
survival advantage of various cancers including colon, lung, breast and prostate cancer in 
patients taking β-blockers [55-57]. However, patients taking β-blockers for various medical 
reasons may have already chronically elevated levels of catecholamines, which would promote 
cancer progression and worse outcome in cancer-bearing patients. In that sense, the chronically 
elevated NE would be a higher risk than the propranolol itself [58]. A large meta-analysis failed 
to demonstrate strong evidence that β2-AR blockers promote tumor progression [59]. In 
summary, these studies demonstrate that elevated levels of catecholamines as well as blockade of 
the β-adrenergic receptor pathway by propranolol may have some impact in breast cancer 
progression as well as patient survival. 
2.3.2. Pancreatic carcinoma 
 In pancreatic carcinoma, β2-AR was expressed in cell lines. NE promoted increased 
proliferation of these cells in a dose-dependent fashion, also promoted S-phase cell cycle shift 
and decreased cells in the G1/G2 phase. Migration was also increased with NE treatment as well 
as increase in phosphorylation of p38 (MAPK pathway, important in cell proliferation), which 
was blocked by treatment with propranolol [60]. In another study, invasiveness and angiogenic 
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potential of pancreatic carcinoma cell lines were assessed by measurement of matrix 
metalloproteinases (MMPs) MMP-2, MMP-9 and VEGF. Norepinephrine promoted the 
invasiveness of one of the cell lines in a concentration-dependent manner, and NE increased the 
expression of MMP-2, MMP-9, and VEGF. These effects were inhibited by propranolol [61]. 
Furthermore, propranolol significantly suppressed cell invasion and proliferation in comparison 
to β1-adrenergic specific antagonist metoprolol. Treatment with β2-adrenoceptor antagonists 
inhibited activation of transcription factors nuclear factor κB (NF-κB), activator protein 1 (AP-1) 
and cAMP response element binding protein (CREB). β2-adrenoceptor antagonists also 
significantly altered VEGF, cyclooxygenase-2 (COX-2), MMP-2 and MMP-9 expression 
confirming previous findings. The β2-adrenergic antagonists suppressed invasion and 
proliferation by inhibiting both cAMP/PKA and Ras, which regulate activation of the MAPK 
pathway and transcription factors, such as NF-κB, AP-1 and CREB, as well as expression of 
their target genes, MMP-9, MMP-2 and VEGF. β1-adrenergic antagonists suppressed invasion 
by inhibiting only the cAMP/PKA pathway [62]. Proliferation and migration of human 
pancreatic ductal carcinoma is stimulated in vitro by β-AR and subsequent cAMP-dependent 
signaling, which in turn leads to cAMP-dependent release of epidermal growth factor, and PKA-
dependent release of VEGF. These effects were also blocked with propranolol treatment [63]. 
Another study using isoproterenol (a non-selective β-AR agonist) significantly increased cell 
proliferation of a pancreatic ductal carcinoma cell line in a dose-dependent manner, with 
concomitant activation of ERK/MAPK signal pathway as well as increased levels of 
phosphorylated ERK [64, 65]. It has been previously demonstrated that β2-AR causes activation 
of the extracellular-signal regulated kinase 1/2 (ERK 1/2).  
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In vivo, mice carrying xenograft tumors had enhanced tumor growth caused by 
isoproterenol, which was suppressed by propranolol [64]. Taken together, these studies suggest 
that blocking the adrenergic pathway using propranolol may have some impact in pancreatic 
carcinoma progression. 
2.3.3. Ovarian carcinoma 
 Immunohistochemistry demonstrated stress-induced increases in levels of basic fibroblast 
growth factor (bFGF), MMP-2 and MMP-9 proteins in ovarian carcinoma. Catecholamines have 
previously shown to promote VEGF production by ovarian cancer cells in vitro [66, 67].  
Chronic behavioral stress resulted in higher levels of tissue catecholamines, greater tumor 
burden and more invasive pattern of ovarian cancer growth in a mouse model; effects which 
were mediated by β2-AR activation of PKA signaling in the cancer cells [68]. Another 
interesting study by Thacker et al used periodic physical restraint to stimulate chronic stress in 
nude mice inoculated with human ovarian carcinoma cells in the peritoneal cavity. In mice 
receiving 0, 2 or 6 hours of immobilization daily for 21 days, the number of tumor nodules 
increased by 259% in the 2 hr stress group and 356% in the 6 hr stress group compared to 
unstressed mice. Mean tumor weight increased 242% in the 2 hr stress group and 275% in the 6 
hr group compared to unstressed mice. Social isolation as an alternative stressor also showed a 
187% increase in tumor weight and a 255% increase in nodule count compared with group-
housed control animals. Stressed animals and non-stressed mice treated with isoproterenol and 
terbutaline (β-agonists) had both significantly enhanced mean vessel density (MVD) counts (a 
measure of angiogenesis [69]) and that effect was blocked by propranolol. This was 
accompanied by significant elevation of VEGF protein and mRNA within tumor tissue.  
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 In another model investigating the effects of surgical stress in tumor development, mice 
were injected with ovarian carcinoma cells and 4 days later subjected to either a laparotomy 
procedure (larger incision, more tissue handling and stress) or a laparoscopy procedure (less 
invasive, less stress). Mice in the laparoscopy group had significantly lower tumor weight 
compared to mice in the laparotomy group. In the immediate postoperative period, serum levels 
of VEGF and MMP-2 were significantly lower in the laparoscopy group as well, further 
supporting the mediators of stress-induced tumor progression [70]. Lee et al. had also 
demonstrated previously that surgery significantly increased MVD and VEGF expression, which 
were blocked by propranolol treatment in mice injected with ovarian carcinoma cell lines [71]. 
The stress of surgery is suggested to facilitate the post-surgery growth of pre-existing 
micrometastases and small residual tumors [72-74]. Taken together, these studies indicate that 
psychosomatic and surgical stress, both present in cancer patients, are linked to tumor growth 
and angiogenesis and propranolol appears to ameliorate these effects.  
2.3.4. Prostatic carcinoma 
 Many studies have also been performed investigating the role of β2-AR in prostatic 
carcinoma. Among the studies investigating possible molecular pathways involved in β blockade 
and prostatic carcinoma, there appears to be a relationship between β2-AR and histamine, as 
histamine augmented β2-AR-induced cAMP accumulation independently of known histamine 
receptors [75]. β2-AR activation also promoted prostate cancer cell proliferation and cell 
migration through increasing cellular cAMP and ERK 1/2 activation in another study, where it 
also demonstrated the involvement of β-arrestin in this process (β-arrestin participates in agonist-
mediated desensitization of G protein-coupled receptors). The formation of β-arrestin 2/c-Src 
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complex was a key factor in this process [76]. An experiment was performed where PC-3 
xenografted mice were implanted with a norepinephrine-releasing micropump which 
subsequently led to a 1.6 fold increase in tumor metastasis compared to control [77]. In addition, 
behavioral stress activated β2-AR signaling and led to inhibition of apoptosis and accelerated 
cancer development in mice. The effects of stress were prevented with treatment using a β2-AR 
selective antagonist [78]. 
β2-AR is a known activator of the androgen receptor, and this receptor is upregulated in 
androgen-independent prostatic carcinoma cell lines. Expression of this receptor is greater in 
malignant cells compared to benign hyperplasia or normal tissue [79]. One study showed that NE 
drives metastasis of PC-3 cells in BALB/C3 nude mice and this process is inhibited by β-
blockers [77]. Loss of BARK-1 in a group of patients with high-grade prostatic carcinoma could 
indicate a possible pathway of prostate cancer development involving β2-AR signaling [80]. 
BARK-1 is a serine/threonine kinase that desensitizes the receptors from catecholamine over-
stimulation (negative feedback via recruitment of beta-arrestin) [81]. In another study, β-blocker 
use was not associated with increased risk of prostatic carcinoma development or overall 
mortality, however a subgroup of men treated with androgen deprivation therapy and a β-blocker 
had a fivefold reduced prostatic carcinoma specific mortality [82].  
In summary, these studies indicate that prostatic carcinoma express the β2-AR, β2-AR 
activation promote prostate cancer cell proliferation and cell migration, mice exposed to 
increased levels of catecholamines have increased metastasis and men treated with β-blockers 
may have reduced cancer-related mortality. 
2.3.5. Other malignancies 
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 Stress has been suggested as a possible factor in human colorectal carcinoma 
development. In one study looking at the effects of chronic restraint stress in nude mice bearing 
human colorectal carcinoma xenografts, adrenergic signaling-dependent activation of ERK 1/2 
promoted cell proliferation, and β-adrenergic antagonism inhibited proliferation and decreased 
phosphorylation of ERK 1/2 in vitro and in vivo. Norepinephrine and epinephrine enhanced 
colorectal carcinoma cell proliferation and viability in cell culture as well as tumor growth in 
mice. These effects were antagonized by propranolol and phentolamine (α-AR antagonist) [83]. 
The first epidemiological investigation of the effect of post-diagnostic β-blocker usage on 
colorectal cancer-specific mortality showed no association. There was some evidence of a weak 
reduction in all-cause mortality in β-blocker users which was in part due to the marked effect of 
atenolol on cardiovascular mortality [84].  
Melanoma cell lines also expressed β1 and β2-ARs. Norepinephrine and E increased 
metalloprotease-dependent motility, released interleukin-6 (IL-6), interleukin-8 (IL-8) and 
VEGF. The effects of these catecholamines were inhibited by propranolol [85].  Interleukin-6 is 
involved in the host immune defense mechanism as well as the modulation of growth and 
differentiation in various malignancies [86]. Increased expression of IL-8 and/or its receptors has 
been characterized in cancer cells, endothelial cells, infiltrating neutrophils, and tumor-
associated macrophages, suggesting that IL-8 may function as a significant regulatory factor 
within the tumor microenvironment [87]. Expression of β-ARs had been previously identified in 
melanoma cell lines as well as human melanoma biopsies and NE upregulated production of 
VEGF, IL-8, and IL-6 in the cell lines [88]. Overall, the results from preclinical studies support 
the suggestion that β-blockers could provide a clinical benefit in melanoma progression however 
epidemiological studies are limited by sample size, which is also a limitation in breast, colorectal 
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and prostatic carcinoma studies [89]. In patients with melanoma, the β-blocker-treated group had 
an overall improved survival after a median follow-up of four years and for each year of β-
blocker use, the risk of death was reduced by 38% [90]. Another study found that both β1 and 
β2-ARs are expressed in tissues from benign melanocytic nevi, atypical nevi and malignant 
melanomas and that expression was significantly higher in malignant tumors.  
 In an in vitro multiple myeloma study, propranolol IC50 values (concentration of 
propranolol required for 50% inhibition of proliferation) were decreased over time. There were 
also significant increases in caspase 3 activity, in apoptotic cell population, and a decrease in 
expression levels of Bcl-2 (anti-apoptotic protein) in response to propranolol treatment [91]. 
Caspase-3 is an executioner caspase protein, involved in the process of apoptosis (programmed 
cell death). Another study showed NE-induced secretion of VEGF in 3 multiple myeloma cell 
lines [92].  
 In conclusion, although the relationship of stress and tumor development/progression has 
been more extensively studied in a number of specific carcinomas (breast, ovarian, prostatic, 
colorectal, pancreatic), it appears to influence non-carcinoma malignancies as well (melanoma, 
myeloma). This illustrates how broad this research field is and indicates that propranolol may 
have the potential to be of benefit in the treatment of many other tumors. 
2.4. Propranolol 
Propranolol is an attractive potential anti-neoplastic therapeutic option since it is 
affordable, easily obtainable in the market and the pharmacokinetics have been established for 
humans [93] and dogs [94]. It is a non-selective β-blocker, available as propranolol 
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hydrochloride, under the brand name Inderal® in North America by AstraZeneca®. It has been 
mainly used for the treatment of hypertension, although other conditions reported include 
tachyarrhythmias [95], tachycardia, essential tremor [96, 97], migraine [98, 99], post-traumatic 
stress disorder [100-104], glaucoma [105], akathisia (restlessness) [106], schizophrenia (elevated 
levels of norepinephrine may play a causative role in the development of this disease) [107], 
adrenergic urticaria [108], treatment of burn patients [109-112] and anxiety [113, 114]. 
In human patients, receiving the diagnosis of cancer creates significant levels of 
emotional distress, with intrusive thoughts (emotional memories, flashbacks, nightmares, and 
intrusive images) being the most common manifestation among breast cancer survivors. Recently 
diagnosed female breast and colorectal cancer patients using β-blockers reported less cancer-
related psychological distress [115]. Although direct psychological stress may not be an 
important feature in canine cancer, propranolol could potentially help to control the anxiety 
associated with repeated hospital visits required for treatment.  
Side effects of propranolol reported in humans most commonly include hypotension, 
hypoglycemia, bradycardia, bronchospasm, sleep disturbances (nightmares), acrocyanosis 
(cyanotic extremities). Other fewer reported side effects include gastroesophageal reflux, nausea, 
vomiting, diarrhea, somnolence, hyperkalemia, tumor lysis syndrome, psoriatic drug rash, 
respiratory syncytial virus exacerbation, and dental caries [116-119]. Propranolol is 
contraindicated in patients with asthma, heart block and sinus bradycardia. The most serious side 
effect of propranolol is hypoglycemia [120, 121]. Propranolol is thought to cause hypoglycemia 
by inhibiting glycogenolysis, glyconeogenesis, and lipolysis. Children have lower glycogen 
stores and higher glucose consumption rates when fasting and, therefore, are more susceptible to 
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hypoglycemia than adults [122]. Side effect incidence, however, does not appear high. A recent 
retrospective study revealed that only 7.6% (10/132) of the children who received propranolol 
treatment had to discontinue it due to side effects. No adverse effects requiring hospitalization 
were recorded. [123]. 
In dogs, propranolol is indicated for the treatment of hypertension, atrial fibrillation, 
tachyarrhythmias [124, 125], myocarditis [126], ventricular premature contractions and 
arrhythmias caused by digitalis toxicity [127]. It is also useful in the treatment of hypertrophic 
cardiomyopathy especially when associated with hyperthyroid disease in cats (as it inhibits 
conversion of thyroxine to triiodothyronine) [128] and for urinary retention (stimulates bladder 
contraction) [129]. It is contraindicated in patients with congestive heart failure unless it is 
secondary to a tachyarrhythmia responsive to beta-blockade. The drug is also contraindicated in 
patients with 2nd or 3rd degree heart block, sinus bradycardia, asthma and thromboembolic 
disease. It should be used with caution in diabetic patients due to risk of hypoglycemia as 
described in humans. Side effects are similar to humans and include hypotension, bradycardia, 
hypoglycemia, decreased cardiac contractility, bronchoconstriction, peripheral vasoconstriction 
and diarrhea. It is recommended that propranolol therapy be gradually withdrawn due to possible 
“rebound” effect of catecholamines to the chronically suppressed β2-AR, leading to tachycardia, 
arrhythmias and hypertension.  
Possible drug interactions with propranolol include [130]:  
• Delayed gastrointestinal absorption of propranolol by antacids 
• Additive toxic effects when used concomitantly with quinidine, procainamide and 
lidocaine (although anti-arrhythmic effects are enhanced) 
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• Hypotensive effects are enhanced by chlorpromazine, cimetidine, furosemide, 
phenothiazines and hydralazine 
• Increased serum levels of lidocaine  
• Increased effects of tubocurarine and succinylcholine 
• Increased action of terbutaline 
• Antagonizing effects on epinephrine and phenylpropanolamine 
• Antagonizing bronchodilatory effects of theophylline 
• Bradycardia may be potentiated by concurrent use of digitalis 
• Anti-hypertensive effects of propranolol can be inhibited by concurrent use of 
salicylates 
• Propranolol’s effects can be decreased by concurrent use of thyroid hormone 
supplementation and the dose of propranolol may require a decrease in animals 
receiving methimazole  
A pharmacokinetic study of propranolol in dogs used a racemic mixture as prepared for 
pharmaceutical use. A half-life of 1.09 +/- 0.33 hours was observed, which was not different than 
what was previously reported for a levo isomer given as an IV bolus, however the distribution 
volumes were significantly greater. A mean value of 6.5 L/Kg was observed with a range from 
3.44 to 10.47 L/Kg. Total body clearance was calculated to average 68 mL/min/Kg. Both hepatic 
and extra-hepatic clearance of propranolol was suggested, and approximately 90% of propranolol 
is extracted from the blood as it passes through the liver. This extensive extraction results in poor 
bioavailability, with only 2-17% of the dose reaching the systemic circulation unchanged. 
Systemic availability increased substantially with multiple dosing (2.1-5.5 mg/Kg every 6 hours), 
reaching up to 10.7 times greater than predicted by single dose. Propranolol is rapidly absorbed 
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with an absorption half-life of 17 minutes. Mean CpMax measured in 5 dogs receiving 40 mg 
(2.1-5.5 mg/Kg) in multiple oral doses was 79.54 ng/mL (range 21-162.5), which is equivalent to 
a mean of 0.3 µM (range 0.08-0.62 µM) [127]. Another recent study with single administration 
of three 40 mg tablets revealed a Cmax of 191.4 +/- 56.52 ng/mL (0.73 +/- 0.21 µM) [131]. 
Propranolol is available in tablets containing 10, 20, 40, 60, 80, 90 mg and oral solution 
containing 4 and 8 mg/m. Injectable propranolol is available in 1 mg/mL concentration. Standard 
dosage in dogs: 0.1-0.2 mg/Kg orally every 8 hours (maximum 1.5 mg/Kg), intravenously 0.02 
mg/Kg over 5-10 minutes (maximum 1 mg/Kg) [132, 133]. 
2.5. Propranolol and infantile hemangioma 
Fairly recently (2008), propranolol was serendipitously discovered to be effective for the 
treatment of infantile hemangioma after two children who were treated with propranolol for 
cardiomyopathy were observed to have their hemangioma regress [5]. Based on this observation, 
the authors decided to treat nine additional children with propranolol and observed similar 
results. Prior to this discovery, hemangiomas were treated with corticosteroids as a first line of 
therapy, with other options including interferon alpha, vincristine or surgical removal if the 
hemangiomas were progressing despite high dose of corticosteroids [134, 135]. Propranolol thus 
came as an effective, inexpensive option for treatment of complicated hemangiomas.  
Infantile hemangiomas (IH) are the most common tumors of early childhood, affecting 
about 5-10% of infants. It is three times more common in females than males, and most prevalent 
in Caucasian children [136]. In general is not considered a severe disease, since most IH will 
spontaneously regress necessitating no additional treatment. However, approximately 12% of IH 
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are complicated cases in which the location or the speed of growth can promote significant 
morbidity including disfigurement, ulceration, bleeding, visual compromise, airway obstruction, 
congestive heart failure and rarely death [137]. Most IH undergo rapid proliferation during the 
first months to year of life, reaching an average size of 2-20 cm. These lesions then undergo a 
slow involution period over several years and are generally fully regressed by 5-10 years of age 
however the duration and rate of growth are variable [136-138]. 
Histologically these tumors are composed of a mixture of clonal endothelial cells 
associated with pericytes, dendritic cells and mast cells [139]. They are densely packed over-
proliferating capillaries with the absence of an open lumen.  The origin is still unclear with some 
studies suggesting aberrant transplantation of placental endothelial cells [140], predisposing 
genetic factors [141, 142] and/or tumor stem cell components [136, 143]. 
The molecular mechanisms behind the development of infantile hemangioma are still 
under investigation. In the early phase of the disease development, angiogenic and growth 
factors can contribute for tumor progression; in the late and involuting phase of the disease it is 
thought that apoptosis is involved. The proposed mechanisms of propranolol effects include 
inhibition of angiogenesis; early vasoconstriction of the tumor (attributed to the blocking of 
nitric oxide production) which causes the softening of the tumor as well as change in color from 
red to purple and later promotion of tumor apoptosis [5]. 
During the growth or proliferative phase, two main pro-angiogenic cytokines have been 
implicated: VEGF and bFGF [139, 144-146]. Studies have shown that both endothelial and 
interstitial cells are actively dividing in that phase. Propranolol has been implicated in 
suppression of VEGF protein expression in hemangioma-derived endothelial cells in a dose-
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dependent manner (25-100 µM) and induced apoptosis by activation of the caspase cascade 
(caspase 3 and caspase 9) after 100 µM treatment of propranolol [147]. Serial serum VEGF 
decrease was also demonstrated in clinical patients after initiating propranolol treatment. This 
same study demonstrated a decrease in serum MMP-9 as well, suggesting another mechanism of 
tumor control by propranolol [148]. Another study demonstrated a decrease in the VEGFR 
(VEGF receptor) protein expression after 48 and 96 hours of cell treatment with higher 
concentrations of propranolol (200-300 µM). Interestingly, there was upregulation of mRNA 
expression but downregulation of VEGF by propranolol, indicating an inhibition in mRNA 
translation into VEGF protein. This inhibition in VEGF was mediated by hypoxia-inducible 
factor 1-alpha (HIF-1α), which is a transcription factor that becomes stabilized in hypoxic 
situations. In a normoxic environment, HIF-1α is rapidly degraded; in hypoxia it persists as a 
transcription factor for many genes including VEGF, ultimately contributing to angiogenesis. 
Another finding was decrease in phosphorylation of PI3/Akt and p38/MAPK in a dose-
dependent fashion [149]. In another study, there was an increase in phosphorylation of p38 in 
propranolol-treated IH. Since p38 regulates the production of inflammatory mediators such as 
TNFα, IL1β and COX-2 [150], one proposed mechanism of IH remission could be due to 
immune-mediated responses [136]. Propranolol treatment also caused decreased levels of 
phosphorylated cofilin. Cofilin is a cytoskeletal-binding protein critical for actin microfilament 
dynamics and reorganization that severs and depolymerizes actin filaments [151]. Cofilin 
phosphorylation could lead to increased cofilin-mediated actin severing, which would disrupt 
cell migration and affect cell proliferation because the actin cytoskeleton is intimately related to 
regulation of the cell cycle progression [136, 152]. Propranolol also disrupted the cell cycle by 
decreasing the expression of key cyclin proteins (cyclin A1, A2, B2, D2 and D3) and increased 
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the expression of important cell cycle inhibitors (p15, p21, p27). No change was noted on 
expression of cyclin-dependent kinases Cdk2 and Cdk4 [136]. Propranolol inhibited cell 
proliferation at an IC50 of 50 µM and induced an increase in the proportion of cells in the G1 
phase while reducing the proportion of cells in S and G2/M phase [136]. Propranolol did not 
induce apoptosis of endothelial cells at 50 µM, nor promoted cleavage of caspase 3 and caspase 
9, in contrast with pro-apoptotic effects stated by other studies described in this text. Cell 
migration (assessed by the scratch/wound healing assay) was significantly inhibited after 
endothelial cells were treated with propranolol at 50 µM for 12 hours [136].  
HIF-1α serum levels were found elevated in children with proliferative hemangiomas 
[153, 154]. HIF-1α protein was decreased in a dose-dependent manner after treatment with 
propranolol, which was evaluated both by Western blot and ELISA. Another possible pro-
angiogenic pathway, NF-κB (nuclear factor kappa-β), was analyzed and was upregulated by 
treatment with propranolol, indicating a possible compensatory angiogenic mechanism by the 
tumor [149]. NF-κB constitutes a non- HIF-1α dependent pathway resulting in VEGF-A 
expression and angiogenesis [155]. Interestingly, the same experiments looking at cell viability, 
migration, tubule formation, RT-PCR, flow cytometry, western blots and ELISA were performed 
in hemangioma endothelial cells and repeated in human umbilical vein endothelial cells 
(HUVEC) used as control cells, with the downregulation of VEGF, VEGFR and HIF-1α not 
observed in control cells, indicating that the effects of propranolol were confined to the 
hemangioma endothelial cells only. Propranolol was also observed to inhibit cell migration and 
tubule formation. Apoptosis of hemangioma endothelial cells, but not hemangioma stem cells, 
was demonstrated in another study [149]. This could explain the rebound growth of 
hemangiomas after propranolol therapy has been discontinued [156-158]. Propranolol also 
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promoted adipogenic differentiation of hemangioma stem cells (involution) [159]. In another 
study propranolol did not promote apoptosis of hemangioma stem cells at a concentration of 50 
µM; the half maximal inhibition was 133 µM, which is well above the biologically achievable 
dose in humans. Inhibition of proliferation was also not achieved in this study. High levels of 
VEGF and bFGF were observed in proliferating IH tissue. At low concentrations (0-20 µM), 
propranolol was capable of decreasing the VEGF mRNA and VEGF protein levels in 
hemangioma-derived stem cells (HemSCs). There was downregulation of bFGF by HemSCs 
however it was less pronounced than VEGF. The proportion of VEGF-positive HemSCs was 
very low in IH tissue [160]. Zou et al showed that propranolol did not affect proliferation of 
endothelial progenitor cells, but it did inhibit migration of these cells in a dose-dependent (0-100 
µM) and time-dependent (24-72 hr) manner. This same study investigated the effects of 
propranolol in the expression of CXCR4, which was suppressed via Akt and MAPK pathways 
[161]. CXCR4 is a receptor for stromal cell derived factor 1α, which promotes mobilization of 
the endothelial progenitor cells from the bone marrow to the site of vasculogenesis [154]. 
In summary, while there is still active research into the molecular pathways involved in 
the response of infantile hemangioma to propranolol, most studies suggest that the effects of 
propranolol are related to suppression of angiogenesis. Some studies also indicate an effect in 
endothelial cell proliferation and survival.  
2.6. Canine Hemangiosarcoma 
 Hemangiosarcoma (HSA) is a malignant neoplasm of vascular endothelial origin. This 
cancer occurs more frequently in dogs than in any other species [2, 3]. It accounts for 2.3 to 3.6% 
of skin tumors in dogs and 45 to 51% of splenic malignancies [2, 3, 162-164]. Like majority of 
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cancers, it affects mostly middle-aged to older animals [163, 165-168]. Breeds that appear 
overrepresented include German shepherds, Golden retrievers and Labrador retrievers [163, 165, 
168-170]. The most common primary site for HSA is the spleen, with other frequent sites include 
the right atrium, skin, subcutis and liver [1, 2, 165, 166, 168, 169, 171-174]. 
Being a vascular malignancy, molecular pathways involving angiogenesis have been 
explored to further clarify the development of this disease. VEGF expression has been 
demonstrated in canine studies [175-177] and plasma levels of VEGF were higher in dogs with 
HSA compared to healthy dogs [178]. There was no marked difference between VEGF levels in 
effusions associated with malignant versus nonmalignant diseases [179]. Other angiogenic 
cytokines important in HSA include bFGF and angiopoietin 1 (Ang-1) [177, 180]. These 
cytokines can be secreted by the tumor cells leading to an autocrine growth signaling or can be 
secreted by other cells within the microenviroment leading to paracrine stimulation. Another 
study showed a significantly higher proportion of platelet derived growth factor (PDGFR-β) 
expression in HSAs compared to cutaneous hemangiomas [181]. 
Mutations in tumor suppressor genes could provide a possible etiology for the disease, 
however studies suggested that p53 (tumor suppressor gene) and Ras (oncogene) mutations are 
infrequent in canine HSA [182-184]. PTEN (tumor suppressor gene) inactivation was 
demonstrated in greater than 50% of evaluated canine HSA samples in one study [185]. Key 
growth and apoptosis regulating proteins such as pRB, cyclin D1, Bcl-2 and survivin appear 
overexpressed in HSA when compared with hemangiomas or normal tissues [183, 186].  
Histopathology is often necessary to establish a diagnosis, since cytology is non-
diagnostic in the majority of time due to excessive bleeding and lack of exfoliation by the tumor 
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[187]. Histologically HSA consists of immature, pleomorphic endothelial cells forming vascular 
spaces containing variable amounts of blood and/or thrombi [188]. Immunohistochemistry for 
factor VIII (Von Willebrand) or CD31 can be used to confirm endothelial origin and support the 
diagnosis [188]. Claudin-5 and CD117 have also been identified as potentially useful markers. 
(Kit) [176, 189]. 
Surgery is the main method of treatment for HSA. Adjuvant chemotherapy is indicated in 
most cases (except for dermal hemangiosarcoma) [190]. Protocols involving doxorubicin are 
most commonly used, including VAC (vincristine, doxorubicin and cyclophosphamide) [191, 
192]; vincristine, cyclophosphamide and methotrexate [168]; doxorubicin and 
cyclophosphamide; doxorubicin and minocycline [193] and single-agent doxorubicin [194-197]. 
Ifosfamide has also been used [198, 199]. Epirubicin and intracavitary pegylated liposomal 
encapsulated doxorubicin do not appear to have advantage over conventional doxorubicin [200, 
201]. Immunotherapy has been investigated as possible treatment strategy, with one study using 
a mixed killed bacterial vaccine following surgery showing some improvement in survival time 
[168], and another study looking at doxorubicin/cyclophosphamide combination with liposome-
encapsulated muramyl-tripeptide-phosphatidylethanolamine (L-MTP-PE) which showed a 
significant increase in median survival time (5.7 to 9 months) with 40% of the dogs experiencing 
long term survival [202]. Radiation therapy is mainly used for non-visceral hemangiosarcoma 
and although it can cause reduction in tumor size it does not significantly change the overall 
survival [203]. A small study looking at a metronomic chemotherapy protocol using NSAID, 
cyclophosphamide and etoposide showed a similar outcome to doxorubicin-based protocols 
[204]. A combination of a dose-intensified doxorubicin protocol with deracoxib (COX2 
inhibitor) was well tolerated but did not result in overall improvement of survival in dogs with 
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splenic HSA [205]. A study investigating the effects of toceranib phosphate (Palladia®), a 
multiple kinase inhibitor (including VEGFR), administered after splenectomy and 5 doses of 
doxorubicin given at 2-week intervals has been conducted and the results showed that the 
administration of toceranib did not significantly improve disease-free interval or overall survival 
time [206]. 
The prognosis for canine HSA is very poor. Hemangiosarcoma typically has a very 
aggressive biologic behavior, with disseminated metastasis occurring very early in the 
development of the disease, except for dermal hemangiosarcomas. Metastasis is typically 
hematogenous or through transabdominal implantation following rupture. The most frequent 
metastatic sites are the liver, omentum, mesentery and lungs. Other reported metastatic sites 
include kidney, muscle, peritoneum, lymph nodes, adrenal gland, brain and diaphragm. Dogs 
treated with splenectomy alone have a survival time that range from 19-86 days and less than 
10% of dogs living one year [3, 164, 168, 207, 208]. Surgery plus adjuvant chemotherapy will 
increase median survival times to 141-179 days, however the one year survival rate is still less 
than 10% [191, 194, 195, 198, 200]. The average survival time of right atrial HSA undergoing 
surgery is 1-4 months [209, 210]. Dermal HSA treated with surgery alone had a median overall 
survival time of 987 days and lingual HSA had a median overall survival time of 553  days [211, 
212]. One analysis of intramuscular and subcutaneous HSA identified 71 cases, the median time 
to tumor progression and overall survival time were 116 and 172 days, respectively and 25% 
survived to 1 year [213]. In summary, the literature on canine HSA describes an aggressive 
cancer. Unfortunately, there has not been substantial improvement in the outcome of dogs with 
HSA and therefore novel therapies are needed.  
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Investigations into the beta adrenergic presence in canine hemangiosarcoma as well as 
the effects of its blockade on cell activity are starting to emerge. One study that evaluated canine 
hemangiosarcoma cell lines as well as mouse angiosarcoma, hemangioendothelioma and human 
dermal microvascular endothelial cell lines revealed that propranolol selectively inhibited 
proliferation, survival, and migration of a panel of malignant vascular tumor cells, indicating that 
the oncogenic properties of these tumor types are driven, in part, by beta adrenergic signaling. 
Propranolol dramatically slowed the proliferation rate of all vascular tumor lines tested, and four 
of the five tumor lines exhibited nearly 100% lethality at doses that had been previously reported 
to be non-toxic for primary cultures of human endothelial cells. This finding suggested that 
malignant endothelial tumors may be more sensitive to beta blockade [214].  
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CHAPTER 3 
MATERIALS AND METHODS 
3.1. Cells and reagents 
Two cHSA cell lines (DEN and Fitz) were provided by Dr. Douglas Thamm (Colorado 
State University). Additional cell lines used as controls included HeLa (human cervical 
adenocarcinoma), MDA-MB-231 (human metastatic breast carcinoma), and MDCK (Madin-
Darby canine kidney) purchased from American Type Culture Collection (ATCC). Cells were 
cultured at 37˚C in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with glutamine 
(2 mmol/L), penicillin (100 IU/ml), streptomycin (100 IU/ml), and 10% fetal bovine serum 
(FBS) in a humidified atmosphere supplemented with 5% CO2. Cell cultures were maintained in 
subconfluent monolayers and passaged as deemed necessary by growth of cell line. 
Propranolol hydrochloride (P) was purchased from Sigma-Aldrich (St. Louis, MO -
catalog # P0884). Norepinephrine bitartrate salt monohydrate was purchased from Sigma-
Aldrich (St. Louis, MO - catalog # A9512). Both reagents were diluted with deionized water 
based on manufacturer’s instructions and solubility provided. 
The anti-β2-AR antibodies (rabbit polyclonal; catalog #AB36956 and #AB135641) used 
for Western blot (WB) and immunohistochemistry (IHC) experiments, respectively, were 
purchased from Abcam Inc (Cambridge, MA). The anti-Src (mouse monoclonal; catalog #2110) 
and anti-phospho-Src  (Tyr 416) (rabbit monoclonal; catalog #2113 and rabbit monoclonal; 
catalog #6943) were purchased from Cell Signaling Technology (Beverly, MA). Antibody anti-
tyrosine hydroxylase (rabbit polyclonal, Abcam #AB112) and anti-CD31 (mouse monoclonal, 
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Dako, North America Inc., #M0823) were used in splenic cHSA tissue samples. The anti-β actin 
antibody used for loading control (rabbit polyclonal; catalog #AB8227) was purchased from 
Abcam Inc. Horseradish peroxidase (HRP) conjugated anti-mouse and anti-rabbit secondary 
antibodies used for WB were purchased from GE Healthcare, UK. Blocking peptide for the β2-
AR WB (catalog #38102) was purchased from Abcam Inc.  
Other reagents used include WB developing solution (SuperSignal West Femto 
Chemiluminescent Substrate, Thermo Scientific, Rockford, IL), bovine serum albumin (BSA), 
milk, tris-buffered saline and Tween 20 (TBST) and hydrogen peroxide (H2O2). 
3.2.  Immunohistochemistry 
3.2.1  Spontaneous canine HSA samples 
Eighteen canine splenic HSA tissue blocks were obtained from the Veterinary Diagnostic 
Laboratory of the University of Illinois at Urbana-Champaign. Paraffin-embedded cell pellets 
were sectioned every 3 microns, placed on positively charged slides, and dried for one hour at 
60°C.  Slides were deparaffinized with two sequential xylene washes, and subsequently hydrated 
using two ethanol baths for five minutes each; followed by a water rinse. Slides were placed in 
3% H2O2 for 15 minutes and rinsed with water. Antigen retrieval was performed with citrate 
buffer microwaved for five minutes. Nonspecific staining was minimized using a blocking 
solution for 30 minutes (5% BSA in PBST).  Slides were then incubated with rabbit polyclonal 
anti-β2-AR antibody at a concentration of 1:35 for 30 minutes at 37°C followed by one hour at 
room temperature. Slides were rinsed twice with PBST and then incubated with a biotinylated 
secondary anti-rabbit antibody for 30 minutes at room temperature. Slides were washed in PBST 
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twice before incubation for 30 minutes with a streptavidin–biotinylated HRP complex, and 
developed with 3,3-diaminobenzidine (DAB) (BioGenex, Freemont, CA). Slides were then 
counterstained with Mayer’s hematoxylin. The negative control samples underwent the same 
process but in the absence of the primary antibody. The isotypic negative control was performed 
using tyrosine hydroxylase antibody (1:200), which is very specific for neuronal tissue. This was 
performed to rule out non-specific Fc receptor binding or other cellular protein interactions, as 
well as confirm the specificity of the primary antibody. The rabbit polyclonal anti-β2-AR 
antibody was validated using canine heart tissue as a positive control as well as mouse spleen 
and kidney [215-217]. All cHSA tissue samples were reviewed by a single pathologist (S. 
Lezmi) and the diagnosis of hemangiosarcoma was confirmed with H&E staining and with IHC 
using a CD31 antibody. CD31 antigen is a marker for endothelial cells and is expressed only by 
endothelial cells, platelets and macrophages; it is conserved in neoplasia arising from endothelial 
cells and validated in canine tissue [218]. The intensity of the β2-AR staining was evaluated 
(scored as strong, mild or none) as well as the localization within the cell (nuclear vs. 
cytoplasmic).  
3.2.2.  Cell pellets 
Fitz and DEN cell lines and a human positive control cell line, MDA-MB-231 [219], 
were used to evaluate β2-AR expression using IHC.  Adherent cell cultures were collected and 
washed in PBS, then pelleted by centrifugation (10,000 RPM for 10 minutes). Each pellet was 
re-suspended in 1 ml 10% formalin for one hour.  Formalin was removed and cell pellets were 
re-suspended uniformly into 1 ml 4% melted agarose gel by vortexing, then immediately 
centrifuged to create an agarose-embedded cell pellet. Cell pellets were then trimmed and 
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processed as for formalin-fixed paraffin-embedded tissue biopsy specimens.  Briefly, paraffin-
embedded cell pellets were sectioned at three microns, placed on positively charged slides, and 
dried for one hour at 60°C.  Slides were deparaffinized with three sequential xylene washes, and 
subsequently hydrated using 100%, 95%, and 70% ethanol for two minutes each; followed by a 
water rinse. Slides were placed in 3% H2O2 in methanol for 15 minutes, and then treated with 
citrate buffer (pH 6.0), placed in a decloaking chamber until the temperature reached 125 °C for 
30 seconds with psi between 18-22, followed by 90°C for 10 seconds.  Slides were removed 
from decloaking chamber and cooled for two minutes followed by a wash in Super Sensitive 
Wash Buffer (BioGenex, San Ramon, CA). The rabbit polyclonal anti- β2-AR antibody was used 
at a concentration of 1:100 for one hour at room temperature. Slides were rinsed with 
SuperSensitive Wash Buffer and treated with Super Enhancer (BioGenex, San Ramon, CA) for 
20 minutes at room temperature, and subsequently treated with Polymer-HRP (BioGenex, 
Fremont, CA) for 30 minutes at room temperature and incubated with DAB (BioGenex, 
Fremont, CA) at room temperature for five minutes.  Slides were washed with SuperSensitive 
Wash Buffer and counterstained with Mayer’s hematoxylin for one minute. Negative control 
samples underwent the same process but in the absence of the primary antibody.  
3.3.  Cell protein extraction 
Cells were grown in culture until confluence and then media was removed and cells were 
washed twice with ice-cold PBS. Cells were then placed in trypsin for five minutes to detach 
from culture plate, followed by addition of complete media to neutralize the effects of trypsin. 
Non-adherent cells were centrifuged at 2,000 rpm at 4°C for five minutes. Supernatant was 
removed and the pellet was washed twice in PBS until all trypsin and media was removed. The 
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pellet was then re-suspended in a solution containing Mammalian Protein Extraction Reagent 
(M-PER, Pierce, Rockford, IL) and Pierce protease inhibitor cocktail solution (Pierce, Rockford, 
IL) diluted 1:100 for final working solution, 10 µL of protease inhibitor to 1000 µL of M-PER. 
This was placed on a shaker for 10 minutes, followed by centrifugation at 10,000 RPM, in 4°C 
for 10 minutes. The supernatant was placed in separate Eppendorf tubes and placed in -80°C 
until analysis.  
3.4.  Western blot analysis 
Cellular protein concentrations were determined using a standard assay kit (Bicinchoninic 
Acid Protein Assay, Rockford, IL). For each protein expression analysis, 50 µg samples were 
electrophoresed on 12% polyacrylamide gel and then transferred to nitrocellulose membrane. 
The membranes were blocked with either TBST with 5% milk (β2-AR and Src) or TBST with 
5% BSA (p-Src), followed by addition of their primary antibody at their specific concentrations 
and exposure time as described in the next sections. In all WBs, secondary HRP-conjugated 
antibody was added at a concentration of 1:1000 for one hour at room temperature after the 
membranes were washed three times with TBST for five minutes, and developed using 
chemiluminescent substrate followed by detection with enhanced chemiluminescence (ECL) 
detection system (Amersham). The blots were imaged using ChemiDoc XRS+ molecular imager 
system (Bio-Rad Laboratories, Hercules, CA) with Image Lab software (version 5.1 build 8, Bio-
Rad Laboratories). The evaluation of protein loading within the blots was performed by 
incubating the membranes with anti-β-actin antibody (1:2000) without the need for stripping the 
membranes since the expected molecular weight of β-actin band was below (46 kDa) the other 
bands evaluated. The membranes were subsequently incubated with the secondary antibody and 
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imaged as described previously. The β-actin loading control is important to verify that the 
amount of protein loaded into the gel is approximately equal.  
3.4.1 β2-AR 
Protein expression of β2-AR was performed via Western blotting using cell lysates from 
Fitz and DEN, as well as HeLa and MDA-MB-231 cells as positive controls [219, 220]. The 
primary antibody was diluted in 5% milk in TBST at a concentration of 1:250. Band specificity 
was confirmed with a matching blocking peptide. For evaluation of the blocking peptide, one 
membrane containing duplicated samples was separated into two membranes becoming two 
exact copies. One portion of the membrane was treated first with the blocking peptide (1:250) 
diluted in 5% milk/TBST for one hour at room temperature, rinsed three times with TBST and 
then incubated with the primary antibody for one hour at room temperature. The other portion of 
the membrane was incubated with only the primary antibody (1:250) for one hour at room 
temperature. Subsequent incubation with secondary antibody and analysis was performed as 
described above.  
3.4.2. Src 
Protein expression of Src was performed via Western blotting using cell lysates from Fitz 
and DEN, and MDCK as a positive control (per antibody manufacturer). Primary antibody 
(1:1000) was diluted in TBST with 5% milk incubated overnight. Basal Src protein expression 
was determined in all three cell lines. In addition, protein expression was assessed in Fitz and 
DEN exposed to different concentrations of NE and P (0.1 and 10 µM) for 24 hours.  
3.4.3. Phospho-Src 
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Protein expression of phosphorylated Src (p-Src) was performed via Western blotting 
using cell lysates from Fitz and DEN. The membrane was incubated overnight with the anti-
phospho-Src (1:1000) antibody diluted in TBST with 5% BSA. For the analysis of 
phosphorylation status of Src after cell treatment, several experiments were performed under 
varying experimental conditions. For positive control of Src phosphorylation in all experiments, 
cells were exposed to 3 mM of H2O2 for five minutes per manufacturer’s instructions. First 
experiment: DEN and Fitz cells were serum-starved overnight then treated with NE (10 µM) or P 
(0.1 µM) for different time exposures (5-30 minutes). Second experiment: To optimize 
visualization of the agonism, Fitz cells were serum-starved for 24 hours then treated with NE (10 
µM) at increasing time-exposure (5-60 minutes). The goal was to determine if phosphorylation 
was positive upon contact with the agonist, if that difference was visible in the WB, and how 
much exposure was necessary for optimal visualization. Third experiment: To determine if 
propranolol could block NE agonism, Fitz cells were serum-starved for 24 hours, then pre-
treated with propranolol (0-0.1 µM) followed by NE treatment (10 µM) at increased time 
exposures (5-60 minutes). Fourth experiment: To determine if propranolol could rescue NE 
agonism, DEN and Fitz cells were serum-starved for 24 hours, then pre-treated with NE (0-10 
µM) for 45 minutes followed by P (0-100 µM) for 24 hours. Band volume analysis was 
performed using Image Lab software and results of the Phospho-Src proteins were adjusted for 
β-actin expression levels used as loading control. For the third experiment, results are expressed 
as p-Src/ β-actin ratio.  
3.5  VEGF ELISA 
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Fitz and DEN cells were plated at a density of 5 x 103 cells/well in a 96-well plate. After 
allowing cells to adhere to the plate overnight, the medium was removed and replaced with fresh 
medium containing NE and/or P. In the first experiment, optimal agonism was assessed using 0-
10 µM NE for 24 hours. In the second experiment, cells were treated with 0-100 µM P with NE 
agonism at 1 µM which was selected as the optimal agonist. Cell culture supernatants were 
harvested and soluble VEGF was determined with a commercially available canine VEGF 
ELISA immunoassay (Canine VEGF DuoSet, R&D Systems, Minneapolis, MN). Differences in 
soluble VEGF secreted by the cHSA cells after each treatment were normalized to cell count 
with the use of a colorimetric proliferation assay (CellTiter 96® AQueous One Solution Cell 
Proliferation Assay – MTS, Promega, Madison, WI) in which optical density linearly correlates 
with viable cell numbers. Specifically, normalized VEGF concentrations were based on the 
average of quadruplicate samples for each experimental group expressed as the following ratio: 
Normalized VEGF = [Calculated VEGF (pg/mL)]/optical density. Samples were performed with 
six replicates per experiment and the results were replicated in three independent experiments. 
3.6. Proliferation assay 
Fitz and DEN cell proliferation was assessed using a commercial colorimetric assay per 
manufacturer’s directions  (CellTiter 96® AQueous One Solution Cell Proliferation Assay – 
MTS, Promega, Madison, WI). This assay measures the number of viable cells by using a 
tetrazolium compound that is bioreduced by metabolically active cells into a colored formazan 
product, which is detected via spectrophotometry. Fitz and DEN were seeded into a 96-well plate 
at a density of 5 x 103 cells/well. After allowing adherence overnight, the cells were treated with 
0, 0.1, 1 and 10 µM of NE or P for 24 hours (first experiment) and with 0, 0.1 or 10 µM NE, 0.1 
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or 10 µM P, 0.1 or 10 µM NE + P (second experiment) for 48 hours. The supernatant was 
removed, and 120 µL of fresh media containing 20 µL of the reagent was added to each well. 
The plate was then incubated at 37°C in 5% CO2 for 1, 2 and 3 hours. At each hour, 
spectrophotometer readings were obtained with a photometric plate reader (Bio-Tek EL 800) at a 
490nm absorbance (wavelength correction set to 570 nm). The data collected for treated cells 
was compared to untreated cells of the same experiment and the difference was calculated as a 
percentage of control cells. The groups were subsequently compared to each other. Samples were 
performed with six replicates per experiment and the results were replicated in three independent 
experiments. 
3.7.  Scratch assay 
Analysis of cell migration was done using the “scratch assay” method [221]. Fitz and 
DEN were grown in culture in 6 well plates until reaching confluence. A scratch was then made 
along the center of the cell culture area using a p200 pipette tip. The medium was then replaced 
with fresh medium containing P (0.01-100 µM) or no treatment (control). An image of the 
scratched cell monolayer was taken (“time 0”) using an inverted microscope (Nikon Eclipse 
TS100) with a mounted digital camera (SPOT Insight QE model #4.2, SPOT Imaging Solutions, 
Michigan, USA). Cells were then grown in culture for 24 hours and another image was taken at 
the same location of the initial image. Captured images were analyzed with Image J software 
(National Institutes of Health, Bethesda, MD). A total of 5 measurements of the gap between the 
cells were taken for each image and average measurements were compared between time 0 and 
24h. Experiment was performed in triplicate with replication. 
3.8.  Statistical analysis 
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 Data from proliferation, VEGF assay and scratch assay were analyzed for normality with 
the Kolmogorov-Smirnov test. Because of the small number of samples, histograms were also 
performed for visual assessment. Data is reported as mean and standard deviation. One-way 
ANOVA was used to evaluate for difference between groups, with Tukey’s multiple comparison 
test to detect a difference between groups. GraphPad Instat 3.1 and GraphPad Prism 6.1 software 
were used for analysis.  
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CHAPTER 4 
RESULTS 
4.1. β2-AR is expressed in spontaneous canine splenic hemangiosarcoma 
  To determine β2-AR protein expression in spontaneous canine hemangiosarcoma, IHC 
was performed. First, the 18 selected tissue samples were confirmed cHSA based on H&E 
staining and positivity for CD31. All tissue samples demonstrated positive β2-AR expression 
(Fig 4.1). Expression of the receptor was identified in the nucleus and cytoplasm, with varying 
stain intensity between tissue samples. Five of 18 (27%) samples had strong intensity and were 
almost diffusely labeled. Eight of 18 (44%) of the samples had only cytoplasmic staining while 
10/18 (56%) had staining of both the nucleus and the cytoplasm. The labeling was frequently 
heterogeneous with some cases presenting large unlabeled areas. Isotype control did not reveal 
any significant non-specific background staining.  
4.2. β2-AR is expressed in canine hemangiosarcoma cell lines 
 To determine β2-AR protein expression in canine hemangiosarcoma cell lines Fitz and 
DEN, WB and IHC were performed. Using WB, we identified a band at the expected molecular 
weight of 55 kDa in both human positive control cell lines MDA-MB-231 and HeLa, as well as 
the canine cell lines Fitz and DEN (Fig. 4.2b). Qualitatively, Fitz appears to have stronger 
protein expression than DEN. Specificity was confirmed with abrogation of the band in the 
presence of a blocking peptide. β2-AR protein expression was also confirmed via IHC on Fitz 
and DEN cell pellets using the same antibody. Cell pellets demonstrated strong, uniform, diffuse 
staining (Fig. 4.2a). 
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4.3. Investigating intermediate signaling via Src/p-Src 
4.3.1. Src and p-Src are expressed in cHSA cell lines 
 Src and phosphorylated Src (Tyr416) are intermediaries involved in signal transduction 
from β2-AR to the nucleus [19]. To determine their involvement in cHSA cells we performed 
WB. We identified bands (Src and p-Src) at the expected molecular weight of 60 kDa in both 
canine positive control cell line MDCK as well as the canine cell lines Fitz and DEN (Fig. 4.3a).  
4.3.2. Propranolol attenuates norepinephrine-induced Src phosphorylation  
 Given that Src and phosphorylated Src (Tyr416) are intermediaries involved in signal 
transduction from the β2-AR to the nucleus, we sought to determine if the β2-AR agonist (NE) 
would lead to phosphorylation of the protein, and if this process could be blocked by the 
antagonist (P). To determine the effects of NE and P on Src and p-Src, we performed WB on 
cHSA cells. In DEN and Fitz cells treated with different concentrations of NE and P (up to 10 
µM), there was no qualitative difference in the expression of total Src (Fig. 4.3b). Both DEN and 
Fitz demonstrated significant basal phosphorylation of Src, suspected to be caused by the FBS 
used in culture. Overnight serum-starvation in DEN and Fitz cell lines did not result in an 
apparent difference in p-Src protein expression with P (low dose 0.1 µM) and increased time-
exposure to NE (Fig. 4.3c). To optimize phosphorylation, Fitz cells were serum-starved for 24 
hours, followed by increasing time exposure to NE. Increased protein expression of p-Src was 
identified, with phosphorylation more pronounced starting at 15 minutes and persisting through 
60 minutes (Fig. 4.3d). Once the positive effects of the agonist NE on phosphorylation were 
demonstrated, we proceeded to evaluate if pre-exposure to low-dose propranolol (0.1 µM) was 
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sufficient to block the receptor to the effects of the agonist. In Fitz cells, NE caused a modest 
phosphorylation of Src and treatment with low-dose propranolol for 24 hours prior to exposure 
led to a modest decrease in phosphorylation. These effects were visible in the WB and therefore 
we proceeded to quantify these results by normalizing the adjusted volume of the p-Src band to 
the matching β-actin band, to ensure that the increased intensity of the band observed was not 
due to increased protein loading (Fig. 4.3e). To determine if propranolol could rescue NE 
agonism, DEN and Fitz cells were serum-starved, pre-treated with NE (0-10 µM), then 
propranolol (0-100 µM). In Fitz cells, low doses of propranolol reduce p-Src compared to 
untreated cells, which is lost at the highest dose in unstimulated cells. In NE-stimulated Fitz 
cells, propranolol reduces p-Src compared to basal levels at all doses. Conversely, in DEN cells, 
propranolol increases p-Src in untreated and NE stimulated cells (Fig. 4.3f) 
4.4. Propranolol affects VEGF secretion of cHSA in vitro 
 After demonstrating the presence of the receptor as well as a possible intermediate 
protein involved in signal transduction, we proceeded to investigate the effects of NE and P on 
cell function activities of cHSA cells. Since propranolol’s ability to inhibit tumor angiogenesis 
has been largely implicated as a primary anti-neoplastic effect, we sought to evaluate the effects 
of NE and P on the ability of cHSA cells to secrete VEGF, a key pro-angiogenic cytokine. In the 
first experiment, we used NE at varying doses (0-10 µM) to assess optimal agonism. Normalized 
to cell count, basal secretion of VEGF was 1098.83 pg/mL and 464.42 pg/mL for DEN and Fitz 
cells, respectively. All doses of NE induced VEGF secretion compared to untreated cells for both 
cell lines. Optimal NE agonism was obtained at 1 µM NE, with a significant increase in VEGF 
secretion compared to control. At optimal NE agonism, there was an increase in VEGF of 29% 
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for DEN cells (p<0.05 for all treatments compared to control), and 2.6-fold increase for Fitz cells 
(p<0.001 for all treatments compared to control) (Fig. 4.4a). Cells were then incubated with the 
selected NE dose of 1 µM combined with varying doses of P starting at a biologically achievable 
dose (0.1 µM) up to 100 µM. No significant differences were noted at low doses, however there 
was a reduction in VEGF secretion in DEN at P ≥ 10 µM (p<0.01) with a maximum decrease in 
VEGF of 21% at 100 µM. Similar results were seen with Fitz, with reduced VEGF secretion at P 
≥ 10 µM (p<0.001) with maximum 44% reduction at 100 µM; a dose dependence was noted in 
the Fitz cell line (p<0.05) (Fig 4.4b). Similar but less profound results were seen without NE 
stimulation (results not shown).  
 
4.5. Propranolol affects cell proliferation of cHSA in vitro 
 
 The metabolic activity of Fitz and DEN, an indirect measurement of cell viability and 
proliferation, was evaluated upon exposure to different doses of NE and P. While there was no 
significant difference noted after 24h incubation, when treated for 48h Fitz exhibited significant 
difference in proliferation between untreated vs 0.1 µM of NE (25% increase) (p < 0.05) and 
untreated vs 0.1 µM of P (30% increase) (p < 0.01). DEN did not exhibit significant difference 
between groups (p > 0.05) (Fig. 4.5) 
 
4.6. Propranolol affects cell migration of cHSA in vitro 
  
 The ability of cancer cells to move within the microenviroment towards the nearby 
vasculature is important in the process of metastasis and therefore we elected to evaluate if P had 
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any effect on cell mobility by evaluating the cells ability to close a gap created between the cells. 
Increasing concentrations of P were used (0-100 µM) and an artificially created gap was 
measured before and 24 hours after treatment. Data is represented as a percentage of the original 
gap (time 0), with being 100% a completely closed gap. The gap remained more noticeably open 
at 10 and 100 µM, being statistically significant at 100 µM when compared to untreated control 
cells (p<0.05) (Fig. 4.6).  
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
 In veterinary medicine, the emotional component of stress may not play an important role 
as it does in humans, however the presence of cancer can lead to microenvironmental stressors 
such as hypoxia and inflammation which may lead to catecholamine release [222, 223]. 
Therefore, stress can play a part in canine tumor progression. In this study we were able to 
demonstrate the presence of β2-AR in all spontaneous splenic cHSA as well as cell lines 
demonstrating the clinical relevance and consistency of expression, and suggesting that this 
pathway may be activated by stress-related catecholamines. The Fitz cell line appeared to have 
stronger protein expression than the DEN cell line. The expression of β2-AR in spontaneous 
tumor samples was heterogeneous in intensity and localization within the cells. The variability of 
IHC staining could be explained by a variable expression of the receptor within the neoplastic 
cells, as well as integrity and detectability of the antigen depending on the time the tissue has 
been stored and the fixative used to initially preserve it as described in a study looking at EGFR 
[224, 225]. Since the samples tested were from different cases obtained over several years, the 
intensity of the staining obtained could be a reflection of the particular sample rather than 
variability within the tumors. However, since tumors undergo frequent mutations, some may 
express more of a particular antigen or receptor compared to others and this variability may 
account for the difference between cytoplasmic versus nuclear staining. Regarding cellular 
localization, upon stimulation β2-AR undergoes internalization, intracellular trafficking and 
recycling and thus variability in cytoplasmic localization may reflect variation in stimulation and 
internalization [226]. Nuclear membrane localization of β1- and β3-AR as well as downstream 
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signaling partners, but not β2-AR, has been reported in normal cardiac myocytes [227]. Our IHC 
results are in concordance with similar studies in human cancer. In a study of β2-AR IHC 
expression in hepatocellular carcinoma, 60% of tumors had moderate/strong staining intensity, 
31% weak staining intensity and 9% negative staining with nuclear and cytoplasmic distribution 
[228]. Another study showed strong β2-AR staining in 41% of angiosarcoma samples that were 
analyzed and a 77% total expression indicating heterogeneity in receptor expression, similar to 
the results obtained in this project [34]. Further evaluation of localization of β2-AR and signaling 
partners could include Western blotting of fractionated cell lysates, confocal microscopy with 
immunofluorescence and other methods.  
 The non-receptor tyrosine kinase Src has been reported as one of the many downstream 
proteins involved in β2-AR activation and therefore we elected to investigate if this pathway is 
indeed activated and blocked by β2-AR agonism/antagonism [19]. After initially demonstrating 
the presence of Src within the cell, we proceeded to verify if this protein is phosphorylated by 
NE. The initial challenge was to overcome the strong basal phosphorylation of this protein 
within the cHSA, which did not allow for a difference in visualization between untreated and 
treated cells. Part of this phosphorylation was probably due to the presence of FBS, which 
contains growth factors that can stimulate the Src pathway. After 24h serum-starvation there was 
still p-Src activity within the untreated cells, however it was diminished enough that an 
appreciable difference was seen compared to NE-treated cells. Norepinephrine agonism of Src 
phosphorylation was confirmed, supporting a role for catecholamine-induced tumor stimulation. 
The subsequent experiment was performed with pre-treatment of cells with P, showing a 
decrease in phosphorylation at low doses of P. With NE agonism prior to P treatment (i.e. 
propranolol “rescue”), which may most closely resemble the clinical scenario, P successfully 
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decreased Src phosphorylation in NE pretreated cells, while phosphorylation was variable in 
DEN cells. This may be a factor of β2-AR expression, which was qualitatively higher in Fitz 
cells. The preliminary results of this experiment warrants further investigation of this pathway, 
however due to multiple pathways involved in β2-AR signaling it is possible that alternative 
pathways are stimulated or inhibited with propranolol leading to the effects seen. These effects 
were related to proliferation, VEGF secretion and cell migration. With respect to VEGF 
secretion, cHSA cells secrete basal levels of VEGF with NE causing increased VEGF secretion, 
more evident in the Fitz cell line. This supports our hypothesis that NE would increase VEGF 
secretion as demonstrated in other studies [229]. The increase in VEGF may be a result of Src 
phosphorylation as hypothesized, and the more profound reduction in VEGF in the Fitz cell line 
may be related to the increased β2-AR expression as well as the more consistent phosphorylation 
effects of P. Taken together, this data supports a role for the β2-AR and the potential role of 
propranolol in inhibiting VEGF-mediated HSA angiogenesis.  
 The effects of NE and P on cell proliferation were also investigated. The initial 
hypothesis was that NE would lead to increased proliferation and P would decrease proliferation 
[230]. Interestingly, we found that both NE and P caused an increase in proliferation in Fitz cells 
at 0.1 µM. There is one report in the literature of P inhibiting proliferation of pulmonary artery 
smooth muscle cells at a 10 µM but not at 0.1 µM. The mechanism for this effect on proliferation 
remained unexplained [231]. One possible explanation may be that this β-blocker could act as an 
agonist to a different receptor or pathway involved in cell proliferation. Additional studies such 
as time-dependent effects may elucidate this further. In one rodent study, propranolol caused a 
transient increase in markers of cell proliferation (PCNA, mitotic index) that were abrogated 
with longer term treatment [232]. The variation observed between the different cell lines in this 
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project was also observed in another study, where beta blockade effectively reduced proliferation 
rate among multiple cell lines however some lines were more resistant to these effects than 
others [214]. 
 Our last finding was that P at a high dose (100 µM) had an effect on cell migration. This 
effect has been described previously in human infantile hemangioma endothelial cells and it also 
decreased phosphorylation of cofilin, as a possible mechanism involved (since cofilin is an actin-
severing protein and phosphorylation is an inhibitory event) [136, 233]. The dose necessary for a 
significant effect is not biologically achievable, however a time-dependent effect at lower doses 
was not investigated in this study and is an avenue for further investigation. Decrease in cell 
migration was detected at a 50 µM dose in one study, which was careful to evaluate the effects of 
this dose on net cell proliferation to eliminate inhibition of proliferation as a contributing factor 
[214]. It is possible that our dose of 100 µM is affecting cell proliferation, which is indirectly 
leading to part of the migration effects seen on the scratch assay.  
 In relating this study to the clinical scenario of canine hemangiosarcoma, the finding of 
β2-AR expression in both spontaneous tumors and two cell lines, strong basal phosphorylation of 
Src, as well as consistent agonism of downstream signaling by NE supports a role of this 
pathway in tumor progression. Variability in expression may suggest a variable response to 
pathway blockade. Effects on VEGF secretion and cell migration were most significant at the 
highest doses of propranolol, which are not biologically achievable with single-dose treatment at 
standard doses. The high doses of propranolol needed to impair tumor cell function is consistent 
with that seen in infantile hemangioma – most of these studies show in vitro effect at 100-300 
µM, which is not clinically achievable. However, in infantile hemangioma, continuous treatment 
is used clinically, which may account for the discordancy between in vitro and in vivo effect. The 
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finding of positive effects on Src phosphorylation at low doses in cHSA may also support a 
potential for low-dose propranolol time-dependent effects on VEGF secretion or cell migration, 
although this was beyond the scope of this study. Continuous low dose treatment with 
propranolol would be reasonable in an adjunctive setting in cHSA due to its low cost and side 
effect profile. 
 Although this study indicated the presence of the β2-ARs in cHSA and that propranolol 
exerts some biological effects in cHSA cell lines, it is important to acknowledge some 
limitations of this project. There is no direct evidence that Src is the intermediary pathway 
connecting β2-AR agonism and cell proliferation, VEGF secretion or cell migration since there 
are many other possible pathways involved [19]. We attempted to elicit phosphorylation of Src 
by exposing the cells to NE over time in order to detect the optimal moment at which most of the 
protein is phosphorylated and thus more easily detectable. We were only able to detect a small 
percentage of phosphorylation and even smaller attenuation by propranolol in one experiment. 
The necessary amount of phosphorylated Src protein required for downstream activation of 
subsequent proteins (such as STAT3 [234]) is unknown and could be as low as 1% and as high 
as 100%, therefore the amount of necessary blockade of phosphorylation for biological effect 
could also be variable. The use of an agonist with a stronger affinity for β2-AR, such as 
isoproterenol [235], could lead to greater phosphorylation of Src and allow for more objective 
visualization of the effects of propranolol. The cells were treated with 0.1 µM of propranolol for 
one hour, which is a biologically achievable dose; however it does not represent the exposure 
time to which an animal is subjected to, being a drug of continuous use. The same critique can be 
applied to the other assays in which the cells were treated for either 24 or 48 hours, revealing 
only statistically significant results at higher doses, which are not biologically achievable. Most 
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studies looking at the in vitro effects of norepinephrine or propranolol used high doses of 
agonist/antagonist, probably because it was necessary to achieve significant findings. Drug 
absorption and delivery to the tumor can be variable in each patient depending on tumor blood 
flow and microenviroment, which is one limitation of translating in vitro findings to in vivo 
effects. Additionally, as noted in one study where propranolol did not completely abolish tumor 
cell proliferation in vivo as noted by positive PCNA staining in propranolol-treated tumors, 
single-agent propranolol may not be as effective in tumor control however synergistic effects 
may be observed with chemotherapeutics warranting further investigation into combination 
therapy [214]. 
 In conclusion, our study showed that cHSA express β2-ARs, Src kinase is one pathway 
activated by this receptor and agonism/antagonism of this receptor exerts anti-angiogenic effects 
in VEGF secretion and minimal effect on cell proliferation. Propranolol at high doses affects cell 
migration. Further studies looking at other possible intermediate pathways as well as other 
mechanisms involved in cancer development (matrix metalloproteinases or apoptosis) are areas 
for further investigation.  
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CHAPTER 6 
FIGURES 
Figure 2.1. G Protein-coupled receptor activation (Belmonte S.L and Blaxall B.C., Circulation 
Research 109 (3), 309-319, July 2011).  
 
 
 
 
 
Figure 2.2. G Protein-coupled receptor downstream signaling. (Cole S.W. and Sood A.K., Clin 
Cancer Res 18 (5), 1201-1206, March 2012). 
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Figure 4.1. Expression of β2-AR in spontaneous cHSA. Immunohistochemistry was performed 
on formalin-fixed paraffin-embedded sections containing tissue from splenic cHSA. All samples 
stained positive for the β2-AR antibody and the degree of staining was variable. Examples of 
strong β2-AR stain intensity (top row) and mild β2-AR stain intensity (bottom row) are shown. 
The diagnosis of splenic cHSA was confirmed after review of H&E staining and CD31. Negative 
control was performed using an isotypic control antibody (1000x). 
 
 
 
Figure 4.2a. Expression of β2-AR in cHSA cell lines. Immunohistochemistry was performed on 
formalin-fixed paraffin-embedded sections of agar-embedded cell pellets containing cHSA cells 
Fitz and DEN. Human mammary carcinoma cell line MDA-MB-231 was used as a positive 
control. Negative control was the absence of the primary antibody (10x). 
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Figure 4.2b. Expression of β2-AR protein in cHSA cell lines. Western blot was performed using 
whole cell lysates of Fitz and DEN. Cell lines HeLa and MDA-MB-231 were used as positive 
control. 
 
 
Figure 4.3a. Expression of Src and p-Src in cHSA cell lines. Western blot using an antibody for 
Src and p-Src was performed using whole cell lysates of Fitz, DEN and MDCK (control). For 
better visualization of p-Src the cells were serum-starved and stimulated with 3 mM of H2O2 for 
5 minutes. All cells demonstrated the presence of basal Src protein as well as phosphorylated Src 
protein.  
 
 
 
Figure 4.3b. Expression of Src in cHSA cell lines exposed to different concentrations of NE and 
P. Fitz and DEN cells were treated with different concentrations of NE and P for 24 hours as 
indicated below. Western blot revealed bands of similar size across all treatments, indicating that 
the presence of total Src protein is independent of the stimulus.  
 
 
 
 
 
 
 
 
 
	   52	  
Figure 4.3c. Expression of p-Src in cHSA cell lines during increasing exposure to NE and P. Fitz 
and DEN cells were serum-starved overnight and treated with 10 µM of NE and 0.1 µM of P for 
different lengths of time as indicated below. Despite 12hr serum-starvation there was still 
marked baseline phosphorylation of Src, which did not allow for qualitative distinction between 
control and treated groups. 
 
Figure 4.3d. Expression of p-Src in Fitz cell line during increasing exposure to NE. Fitz was 
serum-starved for 24 hr and subsequently increasingly exposed to 10 µM of NE. There was a 
qualitative difference between untreated control and 15-60 minute exposure.  
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Figure 4.3e. Expression of p-Src in Fitz cell line during increasing exposure to NE after 
pretreatment with P. Fitz was serum-starved for 24 hr and cells received either no pre-treatment 
or 0.1µM of propranolol for 24 hours. Both groups were subsequently increasingly exposed to 10 
µM of NE. There was a modest increase in phosphorylation of Src over time (23% at 60’) and 
there was modestly decreased phosphorylation when the cells had been pretreated with 
propranolol (11% at 60’). This difference was quantified as the ratio of chemiluminescence 
emitted by p-Src and β-actin for each band. 
 
 
 
 
Figure 4.3f. Expression of p-Src in DEN and Fitz cell line pretreated with NE and rescued with 
propranolol.  DEN and Fitz were serum-starved for 24 hr and cells received either no pre-
treatment or 10µM of NE for 45 minutes. Cells were subsequently exposed to 0-100µM of P. In 
non-pretreated Fitz cells, low doses of propranolol reduce p-Src, which is lost at the highest dose. 
With NE agonism in Fitz cells, propranolol reduces p-Src compared to basal levels at all doses.  
In DEN cells, propranolol increases p-Src in untreated and NE stimulated cells. 
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Figure 4.4a. VEGF secretion by cHSA cell lines after treatment with NE. The graph represent an 
average of VEGF secretion by Fitz and DEN quantified by ELISA and normalized to cell count. 
Cells were treated with increasing doses of NE (0-10 µM) for 24 hours.  In both cell lines, 
compared to untreated cells, there is a significant difference in VEGF secretion (DEN p<0.05, 
Fitz p<0.001). Error bars represent SD.  
 
 
 
 
 
Figure 4.4b. VEGF secretion by cHSA cell lines after treatment with NE and P. The graphs 
represent an average of VEGF secretion by Fitz and DEN quantified by ELISA and normalized 
to cell count. All cells were treated with 1 µM NE (agonist) and P at 0-100µM for 24 hours.  At 
propranolol doses of ≥10	  µM, there was a significant difference of VEGF secretion by both cell 
lines compared to untreated cells (DEN p<0.01, Fitz p<0.001).  For Fitz, there was a significant 
difference between 10 and 100 µM. p<0.05. Error bars represent SD. 
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Figure 4.5. Proliferation activity of cHSA cell lines after treatment with NE and P. Fitz and DEN 
were treated with different concentrations of NE and P for 24 hours (top two graphs) and 
subsequently analyzed by MTS assay. There was no statistical difference between the groups in 
both cell lines (p > 0.5). When cells were treated for 48 hours (bottom 2 graphs), Fitz exhibited 
significant difference between untreated vs 0.1 µM of NE (p < 0.05) and untreated vs 0.1 µM of 
P (p < 0.01). Error bars represent SD. 
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Figure 4.6. Migration of cHSA cells when exposed to increasing doses of propranolol. A scratch 
assay was performed with Fitz and DEN exposed to increasing concentrations of propranolol for 
24 hours, and an average measurement of the residual gap in each treatment group was compared 
to an untreated control. There was a significant difference between the untreated group and 100 
µM (p < 0.05). Error bars represent SD. 
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Figure 4.6 (cont). Migration of cHSA cells when exposed to increasing doses of propranolol. A 
scratch assay was performed with Fitz and DEN exposed to increasing concentrations of 
propranolol for 24 hours, and an average measurement of the residual gap in each treatment 
group was compared to an untreated control. There was a significant difference between the 
untreated group and 100 µM (p < 0.05). Error bars represent SD. 
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